Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVE-IT: MIPD of Ustekinumab and Vedolizumab in IBD
NCT06788340Phase 4Not yet recruiting
- Sponsor
- University Hospital Odense
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ustekinumab and vedolizumab in Crohn's disease and ulcerative colitis (UC) (2 arms), sponsored by University Hospital Odense. Primary endpoint: The fraction of patients in steroid-free remission at 48 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
ustekinumabvedolizumab
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06788340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788340.